Maynard Um
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citi, Opens 90-Day Upside CW
-
-
-
-
-
-
-
BofA Securities Upgrades Acadia Pharmaceuticals (ACAD) to Buy
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citi
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $31 at RBC Capital
-
-
-
-
-
-
-
ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at RBC Capital
-
431,644 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

